Anti-BMP1 antibody produced in rabbit

BMP1 (bone morphogenetic protein 1) is a metalloproteinase belonging to the astacin family. This gene is localized to human chromosome 8p21.3, and is alternatively spliced to produce BMP1 and the longer isoform tolloid protein (TLD). This protein is produced as a proenzyme, which consists of leader peptide, a prodomain, one catalytic domain, three CUB domains, and one epidermal growth factor (EGF)-like domain.

Bone morphogenetic protein 1 precursor recombinant protein epitope signature tag (PrEST)

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies^® protocols and other useful information.

BMP1 (bone morphogenetic protein 1) processes the naïve form of extracellular matrix (ECM) proteins to the mature form, and therefore, are involved in morphogenesis. It also controls the processing of multiple growth factors such as, TGFβ, BMP2, BMP4 and GFD (growth differentiation factor) 8. It facilitates the conversion of bone marrow mesenchymal stem cells to mineralized bone cells. Thus, it enhances bone repair. It makes up the BMP1/TLD-like (tolloid-like) complex, which also includes TLD, tolloid-like protein 1 and tolloid-like protein 2. It is involved in the processing of procollagen I C-terminal propeptide (PICP), type II, type III, and type V procollagen and lysyl oxidase zymogen. Mutation in this gene is linked to autosomal recessive osteogenesis imperfecta. During embryogenesis, it facilitates the binding of BMPs to cognate receptors by degrading the BMP-antagonist chordin.

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:

• IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
• Protein array of 364 human recombinant protein fragments.

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide

Corresponding Antigen APREST72700

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.